01.17.22
Nutraceutical ingredient supplier Phynova and InVita, a Russia-based specialist health ingredient distributor, have reached a distribution agreement in which InVita will distribute Reducose for food and supplement applications to customers in Russia, Kazakhstan, Belarus, and Armenia. Reducose is Phynova’s patented and clinically-researched white mulberry leaf extract, studied for its post-meal blood sugar and insulin support. The ingredient also allows for food and beverage products to achieve a low glycemic index.
"We are grateful to Phynova for choosing us as a distributor to promote Reducose in the territory of the Customs Union,” Igor Perepelkin, general director at InVita, said. “The strong scientific base, experience and knowledge of Phynova’s team, and aspiration and competence of the InVita team will make it possible to achieve success in the Russian market. We look forward to long-term and fruitful cooperation.”
“We are delighted to have a distribution agreement with InVita,” Stephane Ducroux, CEO at Phynova, said. “Phynova’s strategy is to partner with market focused experts such as InVita, who have a proven track record of building deep customer relationships and using ingredients with a strong science like Reducose.”
According to Phynova, Reducose has been evidenced to reduce blood sugar and insulin responses after a meal by up to 40%. Reducose is vegetarian, plant-based, and has been the subject of six human clinical trials. Most recently, a double-blind, placebo-controlled clinical study concluded that Reducose supplementation was linked to improved blood sugar and insulin responses to sucrose in a population of 38 participants.
"We are grateful to Phynova for choosing us as a distributor to promote Reducose in the territory of the Customs Union,” Igor Perepelkin, general director at InVita, said. “The strong scientific base, experience and knowledge of Phynova’s team, and aspiration and competence of the InVita team will make it possible to achieve success in the Russian market. We look forward to long-term and fruitful cooperation.”
“We are delighted to have a distribution agreement with InVita,” Stephane Ducroux, CEO at Phynova, said. “Phynova’s strategy is to partner with market focused experts such as InVita, who have a proven track record of building deep customer relationships and using ingredients with a strong science like Reducose.”
According to Phynova, Reducose has been evidenced to reduce blood sugar and insulin responses after a meal by up to 40%. Reducose is vegetarian, plant-based, and has been the subject of six human clinical trials. Most recently, a double-blind, placebo-controlled clinical study concluded that Reducose supplementation was linked to improved blood sugar and insulin responses to sucrose in a population of 38 participants.